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Abstract Although down-regulation of GNG7 in cancer
was reported before, its role in carcinogenesis is poorly
understood. It belongs to a family of large G-proteins that
may be involved in cell-contact-induced growth arrest and
function in tumor suppression. In the present study, we
stained immunohistochemically 188 tumors derived from
larynx or floor of the mouth for GNG7 protein and con-
fronted it with clinicopathologic data. Moreover, we per-
formed bisulfite pyrosequencing to analyze GNG7 promoter
methylation. We identified recurrent loss of GNG7 protein
expression in 68/188 (36%) cases and promoter hyperme-
thylation in (42/98; 43%) primary tumors, predominantly in
young patients (p<0.001). Loss of GNG7 expression corre-
lated with hypermethylation of GNG7 promoter region (p<
0.001). Moreover, loss of GNG7 protein expression corre-
lated with tumor size (p00.012) and lack of cervical metas-
tasis (p00.02) whereas sustained expression correlated with
keratinization (p00.008). Taken together, loss of GNG7
protein expression is a frequent event in head and neck
cancer. Moreover, our data suggest that hypermethylation
of the promoter region of GNG7 is probably the mechanism
of the observed inactivation.
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Introduction
The guanine nucleotide binding protein 7 belongs to the
large G protein gamma family with GTPase activity that is
involved in transmembrane signalling pathways. The in-
volvement of small nucleotide-binding proteins like RAS
or RHO in malignant transformation is well established
(Bos 1989; Symons 1995). In contrast, the role of large G
proteins in carcinogenesis is poorly understood. However,
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nal cancers was reported more than a decade ago (Shibata
et al. 1998; 1999). Additional evidence supporting the
tumor suppressor functionality of this gene was obtained
recently (Ohta et al. 2008). Whether the observed down-
regulation of GNG7 is restricted only to esophageal cancer
as reported by Ohta et al. or extends also to head and
neck tumors of squamous epithelial origin remains so far
unknown (Ohta et al. 2008).
It has been speculated that GNG7 might be involved
in cell contact induced growth arrest and thus block
uncontrolled cell proliferation in multicellular organisms
(Shibata et al. 1999). In light of this hypothesis, cells
encountering other cells would stop proliferating and start
a differentiation process that is mediated via G protein
signalling. A similar process has been described in inver-
tebrates (Saccharomyces cerevisiae) where it has been
shown that G proteins mediate cell contact induced
growth arrest in a mating pheromone-response pathway
(Fujimura 1989; Nomoto et al. 1990).
We recently performed RNA expression profiling in ten
laryngeal cancer cell lines and three non-cancerous controls
using U133 plus 2.0 microarrays (Giefing et al. 2011).
Although, GNG7 was not among the candidate genes inves-
tigated in that study we used the available expression pro-
files to analyze its expression on mRNA level. In this
analysis, transcriptional downregulation of GNG7 (p<
0.01) in tumor cell lines as compared to controls (normal
squamous epithelium) was observed. This downregulation
was further confirmed by quantitative reverse transcription
PCR on RNA from cell lines as compared to non-cancerous
controls (unpublished data).
Hence, we addressed the question if the loss of GNG7
protein expression and its prognostic significance as sug-
gested by Ohta et al. (2008) for esophageal cancer could be
extended to the anatomically and histologically similar
tumors of the head and neck. Therefore we investigated
GNG7 protein expression by immunohistochemistry in
188 primary tumor samples from larynx and floor of the
mouth. In addition, we investigated whether hypermethyla-
tion of GNG7 promoter region might be responsible for the
observed expression silencing.
Materials & methods
Paraffin sections evaluated for protein expression (group A)
Altogether 116 primary squamous cell carcinoma of the
larynx and 72 squamous cell carcinomas of the floor of the
mouth sections were collected with corresponding clinico-
pathologic data of the patients. The sections were obtained
from the Head and Neck Department of the University
Hospital Eppendorf Hamburg, Germany; the Department
of Clinical Pathomorphology, Collegium Medicum in
Bydgoszcz, Poland and the Senckenberg Institute of Pathol-
ogy, University of Frankfurt, Germany and stained toward
GNG7 protein expression. DNA from 15 of the mentioned
paraffin embedded primary laryngeal samples were isolated
and evaluated toward GNG7 promoter hypermethylation as
described below.
Ethical approvals have been obtained from the Ethical
Commissions of the Medical Council in Hamburg, Germany
and the L. Rydygiers’ Collegium Medicum in Bydgoszcz,
Poland. All clinicopathologic data are summarized in
Table 1.
Controls, primary samples and cell lines evaluated
for GNG7 promoter hypermethylation (group B)
Eight buccal swabs (epithelial cells) samples were collected
from inner oral cavity using medical wooden sticks from
eight healthy volunteers for control purposes. Ninety-eight
primary laryngeal squamous cell carcinoma samples were
obtained from the Department of Otolaryngology, Universi-
ty of Medical Sciences in Poznan, Poland. Within this group
44 samples derived from young adult laryngeal cancer
patients defined as age ≤45 years. Approvals from the
Ethical Commission at the Medical University in Poznan
were obtained. The tumor tissues were assessed histopatho-
logically to confirm the presence of at least 80% tumor cell
content. Clinicopathologic data of the patients is summa-
rized in Table 1. Moreover, DNA from 13 laryngeal squa-
mous cell carcinoma cell lines (LSCC) (UT-SCC-6A, UT-
SCC-11, UT-SCC-19B, UT-SCC-22, UT-SCC-29, UT-SCC-
34, UT-SCC-35, UT-SCC-38, UT-SCC-42B, UT-SCC-57,
UT-SCC-106A, UT-SCC-107, UT-SCC-116) characterized
elsewhere was used (Giefing et al. 2011).
DNA from buccal swabs was isolated using High
Pure PCR Template Preparation Kit (Roche, Mannheim,
Germany) and eluted with 200 μl sterile water (instead
of elution buffer delivered in the kit). Paraffin embedded
samples were deparaffinized by xylene washing, then
hydrated and homogenized prior to DNA isolation.
Thereafter, DNA was isolated from all samples according
to the standard procedure (proteinase K digestion, phenol/
chloroform extraction and ethanol precipitation). For
pyrosequencing, 1μg DNA from each sample was bisulfite
converted using the EpiTect DNA Modification Kit
supplied by Qiagen (Qiagen, Hilden, Germany).
Immunohistochemical staining of samples from group A
GNG7 immunohistochemical staining was performed using
a polyclonal rabbit antibody (sc-377, Santa Cruz Biotech-
nology, Santa Cruz, USA, dilution 1:100). Tissue sections
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occurred at 4°C overnight. Antibody binding was detected
using the Dako Envision Detection System (DAKO,
Glostrup, Denmark). Normal squamous epithelium was an-
alyzed for the physiological pattern of GNG7 protein ex-
pression. As control for specificity, sections of reactive
tonsils incubated with the corresponding blocking peptide
(sc-377P, Santa Cruz Biotechnology, Santa Cruz, USA)
were used. All slides were evaluated by two pathologists
on a multihead microscope.
The cases were assigned to three groups based on the
intensity of GNG7 protein expression. Group one consisted
of negative (−) cases where no specific staining for GNG7
protein was observed; group two were positive (+) cases
with weak staining pattern (weak granular cytoplasmic
staining) and group three were cases with an intense staining
(++, strong homogeneous cytoplasmic staining) reflecting
high expression of the protein. If several staining patterns
occurred in one tumor, the dominating staining pattern was
assessed.
Table 1 Clinicopathologic data of the analyzed head and neck tumors
GNG7 protein expression analysis (group A) GNG7 promoter methylation analysis (group B)
(Number of patients and the % in the analysis) (Number of patients and the % in the analysis)
Total No. of patients 188 98
Localization Larynx 116 (62%) Floor of mouth 72 (38%) Larynx 98 (100%)
Age (years) age ≤45; 44 (45%) age >45; 54 (55%)
median 61 n.a. 43 66
range (38–87) n.a. 34-45 46-79
Gender
male 82 (85%) 49 (69%) 38 (86%) 52 (96%)
female 14 (15%) 22 (31%) 6 (14%) 2 (4%)
not available 20 1 0 0
T classification (size)
pT1 4 (7%) 21 (30%) 5 (11%) 0 (0%)
pT2 4 (7%) 22 (31%) 9 (21%) 5 (9%)
pT3 32 (53%) 15 (21%) 19 (43%) 32 (59%)
pT4 20 (33%) 13 (18%) 11 (25%) 17 (32%)
not available 56 1 0 0
N classification (cervical metastases)
N00 73 (78%) 32 (45%) 30 (68%) 36 (67%)
N01 12 (13%) 15 (21%) 5 (11%) 11 (20%)
N02 5 (5%) 22 (31%) 9 (21%) 7 (13%)
N03 4 (4%) 2 (3%) 0 0
not available 22 1 0 0
G classification (grading)
G1 9 (10%) 3 (4%) 11 (28%) 19 (39%)
G2 67 (71%) 52 (73%) 28 (70%) 28 (57%)
G3 18 (19%) 15 (21%) 1 (2%) 2 (4%)
G4 0 (0%) 1 (1%) 0 (0%) 0 (0%)
not available 22 1 4 5
Overall survival, months
mean 45 41 52 46
median 44 19 56 37
range (1–121) (1–179) (3–129) (0–93)
Smoking habit
smoker 32 (94%) n.a. 41 (93%) 43 (83%)
non smoker 2 (6%) n.a. 3 (7%) 9 (17%)
not available 82 n.a. 0 2
n.a. - not available
J Appl Genetics (2012) 53:167–174 169Bisulfite pyrosequencing of samples from group B
Primers for GNG7 bisulfite pyrosequencing (Forward: GAG
AGGTTTTTTAGGGTGATT; Reverse-5’biotin: TCTTCC
CCAACAAATAAAC; Sequencing: GTTTTTTAGGGT
GATTT) were designed with PyroMark Assay Design Soft-
ware 1.0 (Biotage, Uppsala, Sweden). Primers were verified
for potential SNPs occurrence within primer binding region.
PCR reactions were run using PyroMark kit (Qiagen,
Germany) with the following program: 95°C for 15 min
(HotStarTaq DNA Polymerase); 45x: 94°C for 30 s; 55°C
for 30 s; 72°C for 30 and final 72°C for 10 min. PCR
products were run on 2% agarose gel stained with ethidium
bromide and visualized under UV light (Bioanalyzer, Biometra,
Göttingen, Germany).
PCRproductswerepurifiedpriortopyrosequencingusinga
water pump station and the following buffers: 70% EtOH,
0.2% NaOH and Washing buffer (according manufacturer’s
instructions) (Qiagen, Hilden, Germany). After a final dena-
turation step at 85°C for 2 min sequencing primer was hybrid-
ized. Pyrosequencing was performed using the Pyrosequencer
PyroMarkIDandtheDNAmethylationanalysissoftwarePyro
Q-CpG 1.0.9 (Biotage, Uppsala, Sweden), which was also
used to evaluate the ratio T:C (mC:C) atthe CpG site analyzed.
Foreachpyrosequencingreaction two bisulfitetreatedcon-
trols were included: the totally methylated DNA (Millipore,
Hilden,Germany) and the pooledDNA (mix ofDNAfrom20
peripheralbloodfromhealthydonors,10maleand10female).
Statisticalanalysis–proteinexpressioninsamplesformgroupA
Statistical calculations have been performed using the SPSS
software v.17.0 (SPSS Inc. Chicago, USA). To differentiate the
cases depending on GNG7 protein expression we selected the
GNG7(−) and the GNG7(++) groups for the calculations. Only
in the case of keratinization - to assure a sufficient number of
cases for the analysis - we compared the GNG7(−) against the
merged GNG7(+/++) group. The Kaplan-Meier survival anal-
ysis has been used to analyze the difference in survival time
between head and neck cancer patients depending on the
localization of the tumor (larynx or floor of the mouth) and
depending on GNG7 expression. The Chi-square crosstabula-
tiontesthasbeenusedtotestforthecorrelationbetweenGNG7
expression and the T, N, G classification parameters and kera-
tinization. The number of samples used in various statistical
calculations might differ for the numbers given above as com-
plete clinicopathologic data was not available in all samples.
Statistical analysis – GNG7 methylation in samples
from group B
To calculate a cut-off value for methylation, bisulfite treated
DNA from eight buccal swabs obtained from healthy
volunteers were pyrosequenced. The mean methylation value
for these samples was 2% and standard deviation (SD) was
1%.Thecut-offwassetbysummingthemeanmethylationfor
the buccal swabs samples (2%) and three times the SD and
was 5%. All samples for which the methylation value level
was >5% were assigned as methylated. Statistical calculations
have been performed using the SPSS software v.18.0 (SPSS
Inc. Chicago, USA). The Chi-square crosstabulation test was
used to analyze the correlation between GNG7 methylation
and age.
For further statistical analyses the 44 samples of young
adult patients with different clinical parameters were excluded.
In the remaining samples from group B the Kaplan-Meier test
has been used to analyze the difference in survival time
depending on GNG7 methylation. Moreover, the Chi-square
crosstabulation test has been used to analyze the correlation
between GNG7 methylation and the T, N, G classification and
smoking addiction.
For cell lines, with “significantly downregulated” we
defined significant reduction of GNG7 expression using
the Wilcoxon signed rank test versus at least 2/3 non-
tumor laryngeal controls as described in detail in Giefing
et al. (2011). To correlate GNG7 expression depending on
its methylation status for cell lines where the GNG7 mRNA
expression was known and the 15 samples analyzed both for
GNG7 protein expression and promoter hypermethylation
the Chi-square crosstabulation test was used. The number of
samples used in various statistical calculations might differ
for the numbers given above as complete clinicopathologic
data was not available for each patient.
Results
Loss of GNG7 expression on protein level correlates
with advanced tumor size, keratinization and low metastatic
potential (group A)
First, we analyzed normal squamous epithelium for the
physiological pattern of GNG7 expression. We observed a
weak, granular cytoplasmic GNG7 expression in the spi-
nous layer with an enhanced cytoplasmic expression in the
superficial layer and granular layer, if present (Fig. 1a, ar-
row). In reactive tonsils germinal centers and the keratiniz-
ing parts of the squamous epithelium stained positive. To
analyze the specificity of the GNG7 staining we incubated
reactive tonsils with the corresponding blocking peptide. In
consequently immunostained tonsils no staining was ob-
served demonstrating the specificity of the reaction.
Thereafter, we stained immunohistochemically for GNG7
proteinin188primaryheadandnecktumors.Thirtyonecases
showed an intense staining pattern (++), 89 cases presented
weak GNG7 protein expression (+) and in 68 cases no
170 J Appl Genetics (2012) 53:167–174expression was observed (−) (Fig. 1). Keratinizing tumors
oftenshowedanintensestainingpatternaroundcentralkeratin
pearls(Fig.1c).Reactivesquamousepitheliumadjacentto the
tumors showed an inconsistent expression of GNG7 protein
which was particularly high in cells showing keratinization.
No statistically significant difference between overall
survival and the localization of the tumors in larynx or floor
of the mouth was observed. As a consequence, the highly
clinicopathologically similar groups were merged for further
analyses. Moreover, no difference in the overall survival
depending on GNG7 protein expression in laryngeal and
floor of the mouth tumors together was observed.
Significant correlation between loss of GNG7 protein ex-
pression and tumor size (pT) was identified (p00.012). Loss
of GNG7 protein expression was more frequent in the pT3/4
tumors. In detail, out of 40 GNG7(−) tumors, 31 (77%) were
pT3/4. Similarly, the GNG7(−) cases were overrepresented in
non cervicallymetastasing tumors, where 47/63 (75%) GNG7
(−) cases showed no cervical metastases (p00.02). These
findings suggest that the loss of GNG7 protein expression is
characteristic to large tumors, not metastasing to cervical
lymph nodes. No significant correlation was observed be-
tween GNG7 staining and tumor grade.
Finally, a highly significant correlation was identified
between keratinization and GNG7 protein expression (p0
0.008) showing GNG7(+) and GNG7(++) expression to-
gether to be characteristic for keratinizing tumors. Therein,
21/29 (72%) GNG7 (+/++) positive tumors showed kerati-
nization (p00.008). The results are summarized in Table 2.
GNG7 is frequently hypermethylated in cell lines
and primary tumor samples (group B)
To analyze the methylation level in non-cancerous tissue we
first pyrosequenced eight buccal swaps samples (oral squa-
mous epithelial cells) collected from healthy volunteers.
Based on these results we have established the cut-off for
methylation to 5% as described in the materials and methods
section. Applying this cut-off to the tumor samples pyrose-
quencing results we identified hypermethylation of the
GNG7 promoter region in 8/13 (62%) laryngeal cancer cell
lines and 42/98 (43%) primary tumors.
GNG7 promoter hypermethylation correlates with loss
of GNG7 expression
To analyze if GNG7 mRNA expression in LSCC cell lines
depends on promoter hypermethylation we used U133 plus
2.0 microarray expression profiles from our recent study
Giefing et al. (2011). GNG7 expression and methylation
levels were compared in the very same cancer cell lines. In
detail, expression profiles were available for 10 laryngeal
cancer cell lines (UT-SCC-6A, UTSCC-11, UT-SCC-19B,
UT-SCC-22, UT-SCC-29, UT-SCC-34, UT-SCC-57, UT-
SCC-106A, UT-SCC-107, UT-SCC-116) out of which sig-
nificant downregulation of GNG7 (expression tag
206896_s_at) was observed in six cell lines (UTSCC-11,
UT-SCC-19B, UT-SCC-22, UT-SCC-29, UT-SCC-106A,
UT-SCC-116) compared to non-tumor laryngeal tissues.
Fig. 1 GNG7 immunostaining.
a.Reactivesquamousepithelium
showing GNG7 expression in
keratinizing cells (arrow). b.
Well differentiated squamous
cell carcinoma showing strong
expression of GNG7. c.
Keratinizing squamous cell
carcinoma showing strong
expression of GNG7 in
keratinizing cells (arrow) and
weak expression in the more
basaloid differentiated cells
(arrow with *). d.P o o r l y
differentiated, non-keratininzing
basaloid squamous cell
carcinoma, GNG7-negative.
(All images 200× magnification)
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all six cell lines and additionally in the UT-SCC-107 cell
line. Moreover, DNA from 15 paraffin embedded samples
stained for GNG7 protein expression in group A were ana-
lyzed toward GNG7 promoter methylation by pyrosequenc-
ing. All four samples negative for GNG7 protein expression
were hypermethylated whereas out of the 11 GNG7 express-
ing cases we identified hypermethylation only in two. Taking
together,significantcorrelationbetweenlossofGNG7expres-
sion and GNG7 promoter hypermethylation was observed
(Yates’ corrected p<0.001) (Table 2).
No correlation observed between GNG7 methylation
and overall survival, TNM classification or smoking habit
(group B excluding 44 young patients)
To look for correlation between GNG7 methylation and the
overall survival of patients, we performed a Kaplan-Meier
test but no correlation was observed. Similarly no correla-
tion between the TNM classification or the smoking habit
and methylation was observed.
GNG7 is hypermethylated predominantly in young patients
Last, we addressed the question if there are differences in the
frequency and level of GNG7 methylation between the 44
samples derived from young adult laryngeal cancer patients
and the 54 samples from patients age >45. We observed in the
cohort of young patients a significantly enriched number of
cases with GNG7 hypermethylation (29/44 (66%) hyperme-
thylated cases) (chi-square tests p<0.001) compared to the
group of older patients (13/54 (24%) hypermethylated cases)
(Table2). In addition, samples derived from young patients
were not only more frequently methylated but also the mean
methylation level of 27% was higher as compared to 18% in
the samples from older patients (Fig. 2).
Table 2 Results of statistically significant tests
Analysis Results (number of patients and the % in the analysis) p value
GNG7 protein
expression analysis
(group A)
GNG7 expression (−) vs (++)
depending on the T stage
(T01/2 vs T03/4)
T01/2 T03/4 0.012*
GNG7 (−)n 040 9 (23%) 31 (77%)
GNG7 (++) n022 12 (55%) 10 (45%)
GNG7 expression (−)v s
(++) depending on the
N status (N00v sN 01/2/3)
N00N 01/2/3 0.02*
GNG7 (−)n 063 47 (75%) 16 (25%)
GNG7 (++) n023 11 (48%) 12 (52%)
GNG7 expression (−)v s
(+) and (++) depending
on keratinization (−) vs (+)
K( −) K (+) 0.008*
GNG7 (−)n 027 17 (63%) 10 (37%)
GNG7 (+/++) n029 8 (28%) 21 (72%)
GNG7 promoter
methylation analysis
(group B)
GNG7 nonmethylated vs
methylated depending
on the age of patients
(age ≤45 vs age >45)
age ≤45 n044 age >45 n054 < 0.001*
GNG7 unmethylated 15 (34%) 41 (76%)
GNG7 methylated 29 (66%) 13 (24%)
GNG7 expression and
promoter methylation
Loss of GNG7 expression
vs methylation status
NO loss of
expression
Loss of
expression
< 0.001* (Yates'
corrected)
GNG7 unmethylated 12 0
GNG7 methylated 3 10
T - size of the tumor
N00 - non nodular metastases
N01/2/3 - nodular metastases present
K(−) - no keratinization observed
K(+) - keratinization present
*statistically significant
Fig. 2 Young adult patients show higher mean methylation of GNG7
promoter region than older patients. “+”–mean methylation
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In this study we immunohistochemically stained 188 tumors
from head and neck cancer derived from larynx and floor of
the mouth for the GNG7 protein. Overall, we identified loss
of GNG7 expression in 68/188 cases (36%) and showed that
it is a recurrent event in head and neck cancer. Moreover, in
an independent cohort of laryngeal tumor samples we
detected recurrent hypermethylation of the GNG7 promoter
region in 42/98 (43%) primary tumors. It is noteworthy that
in a cohort of laryngeal cancer cell lines and 15 primary
samples the downregulation of GNG7 gene expression sig-
nificantly correlates with hypermethylation (p<0.001). This
suggests that at least for a subset of cases hypermethylation
is the mechanism behind the observed loss of GNG7 ex-
pression. This is further stressed by the fact that no muta-
tions in the coding exons of GNG7 were identified in a
mutation screen in ten laryngeal cancer cell lines (data not
shown).
In contrast to the recent findings of Ohta et al.
concerning esophageal cancer, we did not observe corre-
lation neither of GNG7 protein expression with overall
survival nor for GNG7 methylation with overall survival
of the patients diagnosed with head and neck cancer (Ohta
et al. 2008). However, since no data on the treatment of
the patients were available the discrepancy might reflect
different treatment modalities of the head and neck cancer
patients as compared to esophageal cancer patients in the
two studies.
Regarding the clinicopathologic parameters, we found
a statistically significant correlation between loss of
GNG7 protein expression and the size of the tumor.
Large tumors (pT3/4) showed more frequent loss of
expression. Likewise, Ohta et al. (2008) reported that
loss of GNG7 expression correlates with the depth of
tumor invasion and aggressiveness.
It is tempting to speculate that loss of GNG7 protein
could be a marker for tumor progression as we detected also
a highly significant correlation between GNG7 protein ex-
pression and keratinization. Keratinization is usually present
in well differentiated tumors and lost during progression
which could be a predictor of early recurrence as presented
recently by Pinto et al. (2010). On the other hand, we
observed no correlation between GNG7 protein expression
and the grading parameter G.
Besides, we found a correlation between loss of GNG7
protein expression and the absence of cervical metastases. In
parallel, we show that loss of GNG7 protein was associated
with large tumors of pT3/4 stage. This is surprising, as in the
investigated cohort the pT3/4 tumors show more frequently
cervical metastases than the pT1/2 tumors. Thus, loss of
GNG7 defines probably a subgroup of locally advanced
tumors with low metastatic potential. One should of course
note that a different mechanism might be responsible for
local metastasis with no relation to GNG7.
Last, we show that GNG7 promoter methylation is sig-
nificantly more frequent in young adult patients age ≤45 as
compared to patients age >45 (p<0.001). Interestingly,
O'Regan et al. showed that promoter hypermethylation of
the most frequently inactivated tumor suppressor gene in
head and neck cancer namely CDKN2A is a more common
event in patients younger than 40 years than in older patients
where genomic deletion was more common (O'Regan et al.
2008). Taken together, this might suggest that epigenetic
silencing of tumor suppressor genes is more prevalent in
young patients and with age shifts toward genomic loss in
line with the general observation that genomic instability
increases with age.
In summary we show here that loss of GNG7 protein
expression is a frequent event in head and neck cancer. Our
results indicate moreover, that GNG7 protein expression is
lost predominantly in advanced T stage tumors with low
metastatic potential. Besides, we suggest epigenetic silenc-
ing as the mechanism of GNG7 gene inactivation which
might be especially true for young adult patients.
Acknowledgements Supported by the Polish Ministry of Science and
HigherEducationgrantN301238736andFörderungNachwuchsforscher
der Goethe Universität Frankfurt (S.H.). M.G. was supported by the
FEBS Long-term fellowship and the “Support for International Mobility
of Scientists” fellowship of the Polish Ministry of Science and Higher
Education. M. Sz. was supported by the EMBO short-term fellowship.
I.S was supported by the Alexander von Humboldt Foundation
fellowship.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res
49:4682–4689
Fujimura HA (1989) The yeast G-protein homolog is involved in the
mating pheromone signal transduction system. Mol Cell Biol
9:152–158
Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M,
Szaumkessel M, Pelinska K, Kiwerska K, Tönnies H, Grenman R,
Figlerowicz M, Siebert R, Szyfter K, Jarmuz M (2011) High
resolution ArrayCGH and expression profiling identifies PTPRD
and PCDH17/PCH68 as tumor suppressor gene candidates in
laryngeal squamous cell carcinoma. Genes Chromosomes Cancer
50:154–166
Nomoto S, Nakayama N, Arai K, Matsumoto K (1990) Regulation of
the yeast pheromone response pathway by G protein subunits.
EMBO J 9:691–696
Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K,
Ishii H, Inoue H, Mori M (2008) Clinical significance of the
reduced expression of G protein gamma 7 (GNG7) in oesophageal
cancer. Br J Cancer 98:410–417
J Appl Genetics (2012) 53:167–174 173O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon
C, Smyth P, Cahill S, Flavin R, Sheils OM, O'Leary JJ (2008) p16
(INK4A) genetic and epigenetic profiles differ in relation to age
and site in head and neck squamous cell carcinomas. Hum Pathol
39:452–458
Pinto LS, de Aguiar FC, Kowalski LP, Graner E, Lopes MA (2010)
FAS and ErbB2 expression in early local recurrent oral cancer. J
Oral Pathol Med 39:176–181
ShibataK, Mori M,TanakaS,KitanoS,AkiyoshiT (1998) Identification
and cloning of human G-protein gamma 7, down-regulated in pan-
creatic cancer. Biochem Biophys Res Commun 246:205–209
Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M (1999) G-protein
gamma 7 is down-regulated in cancers and associated with p
27kip1-induced growth arrest. Cancer Res 59:1096–1101
Symons M (1995) The Rac and Rho pathways as a source of drug targets
for Ras-mediated malignancies. Curr Opin Biotechnol 6:668–674
174 J Appl Genetics (2012) 53:167–174